Medtronic announces ONSET trial results of sensor-enhanced CSII in children

September 04, 2015

Insulin pump therapy at diabetes onset results in lower A1C values (average blood glucose) compared to historical controls (the use of insulin injections during the first 12 months after diagnosis), and improves psychological well being. The sub-group of patients using Personal CGM regularly (at least one glucose sensor per week) experienced significantly lower A1C values (0.5%,> There were significantly fewer episodes of severe hypoglycemia in patients using an insulin pump with Personal CGM compared to those using conventional insulin pumps. In patients using Personal CGM, more frequent glucose sensor use during the first year was associated with significantly less C-peptide loss, and C-peptide values at 12 months were significantly higher in adolescents (12-16 years). In addition, glycemic variability (calculated by mean amplitude glucose excursion, MAGE) was significantly lower compared to the group using a conventional insulin pump with SMBG.

The ONSET trial, conducted in Austria, France, Germany, and Poland, adds to the growing body of evidence that demonstrates using Personal CGM on a regular basis improves glycemic control.

The MiniMed Paradigm REAL-Time System is the world??ôs only system to integrate an insulin pump with Personal CGM. Patients using Personal CGM are able to view glucose sensor data and use this information to understand how diet, exercise, medications and lifestyle affect glucose levels. By viewing graphs and receiving alerts when glucose levels are becoming too high or too low, patients can make more informed therapy decisions to maintain near-normal glucose control.